Dual-specific antibody TR009 / ABL001 targeting VEGF / DLL4 treats gastroesic tumors with encouraging preclinical results

Anti-new blood vessel therapy is an effective strategy in solid tumor therapy, and drug resistance has appeared in anti-VEGF therapy in recent years.
Notch signal transducting is a intercellular signaling path, which plays an important role in tumor new angiogenesy.
in the Notch path, Delta-like liage 4 (DLL4) plays an important role in affecting tumor angiogenesic angiogenesy, which inhibits the formation of new blood vessels and promotes the maturation of new blood vessels.
biopharmaceutical company TRIGR Therapeutics announced today that it has published preclinical results for TR009, a bisceptive antibody developed by the company for VEGF/DLL4 to inhibit the newborn blood vessels of tumors.
results showed that TR009 showed more effective in vitro and in vivo biological activity than monoclonal antibodies only for VEGF or DLL4.
addition, the combination of TR009 with yew alcohol and erythyme can co-inhibit tumor progression in human gastric and colon cancer heterogeneous transplant models.
immunological analysis of tumor blood vessels showed that after TR009 treatment, the expression levels of VEGFR-2 and DLL4 (double targets of TR009) in tumor endoblast cells were significantly reduced.
consistent with previous studies, the data strongly support the interaction between VEGF/VEGFR signal conduction and the DLL4/Notch signal pathline in tumor vein systems.
。